Ramadan, the ninth month of the Islamic lunar calendar, is a period of fasting, prayer, reflection, and community for Muslims ...

We are thrilled to announce our collaboration with Abbott, integrating its world-leading FreeStyle Libre technology 2 as our first CGM partner, marking a significant milestone as we bring our ...

QWINT-3 evaluated the efficacy and safety of once-weekly efsitora compared to once-daily insulin degludec for 78 weeks in adults with type 2 diabetes currently treated with basal insulin.

The QWINT-1 study compared efsitora to daily injections of Sanofi’s SNY Lantus (insulin glargine) for 52 weeks in T2D patients using basal insulin for the first time. The QWINT-3 study compared ...

According to nutritionist Ángela Quintas it all comes down to what you’re eating—and, more specifically, how it impacts your ...

Brazil's National Health Surveillance Agency (Anvisa) has approved the drug Awiqli, produced by the pharmaceutical company ...

compared the efficacy and safety of a basal-bolus insulin regimen with that of sliding-scale regular insulin (SSI) in hospitalized general medical patients with type 2 diabetes. The prospective ...

Novo Nordisk’s bid to provide a once-weekly basal insulin product for people with diabetes, reducing the number of injections needed, has hit a major hurdle in the US. The FDA sent the Danish ...

There is a growing need for additional treatment options for individuals with type 2 diabetes who are being treated with ...

and suspend delivery of basal insulin based on iCGM readings and predicted glucose values. It can also deliver correction boluses when the glucose value is predicted to exceed a predefined threshold.

We encourage biosimilar competition and launched our own lower-priced biosimilar, Rezvoglar, a biosimilar to, and interchangeable with, a competitor’s basal insulin (Lantus), at a 78% lower ...